RecruitingNCT03131531
Bergamo Lymphoid Cancer Registry
Sponsor
A.O. Ospedale Papa Giovanni XXIII
Enrollment
6,000 participants
Start Date
Mar 23, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Male or female patients 18 years or older
- Written informed consent
- Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Exclusion Criteria1
- \- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Interventions
OTHERPatient registry
Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03131531
Related Trials
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT0516951526 locations
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
NCT050924511 location
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
NCT05006716120 locations
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
NCT060263191 location